Objective: Insertable cardiac monitoring (ICM) systems are useful for diagnosing paroxysmal atrial fibrillation (PAF) in cryptogenic stroke (CS). We assessed the initial treatment outcome using insertable cardiac monitors in CS treated by endovascular reperfusion therapy.
Introduction
Insertable cardiac monitoring (ICM) for cryptogenic stroke (CS) has been approved. The incidence of CS based on the Trial Org 10172 in Acute Stroke Treatment (TOAST) classification was 16%-39%. 1) As an etiological factor for CS, latent atrial performed. They consisted of 67 (65%) with cardiogenic cerebral embolism, 11 (11%) with atherothrombotic cerebral infarction, 2 (2%) with Trousseau syndrome, 1 (1%) with aortogenic cerebral embolism, 1 (1%) with cerebral artery dissection, and 20 (20%) with CS ( Fig. 1) . Of the 20 patients with CS, ICM was performed on 10 (10%) according to the guidelines for the diagnosis of CS patients for whom an ICM device may be indicated. A diagnosis of CS was made in accordance with the same guidelines. 4) Necessary items described in the guidelines (cephalic MRI), 12-lead ECG, electrocardiographic monitoring for ≥24 hours, transthoracic echocardiography, diagnostic imaging of the carotid artery, and diagnostic imaging of the intracranial arteries were conducted for all patients. Transesophageal echocardiography (TEE) was performed on all patients. When a right to left shunt was present, ultrasonography of lower limb veins was conducted, and patients definitively diagnosed with cardiogenic, aortogenic, or paradoxical cerebral embolism were excluded. Exclusion criteria included patients definitively diagnosed with cerebral infarction related to large/small vessel occlusion or other etiological factors according to the TOAST classification. 5) Electrocardiographic monitoring was conducted for ≥3 days. Blood coagulation tests for investigating specific etiological factors that may cause cerebral infarction were performed only for patients with a family history or relatively young patients. In all patients, neurologists implanted ICM devices under cardiologists' guidance in the angiography room. Implantation was conducted according to the procedures described in the package inserts of the ICM device Reveal LINQ (Medtronic Inc., Minneapolis, MN, USA). After implantation, the position of the ICM device was confirmed under fluoroscopy using a frontal X-ray tube in the angiography room. After insertion, neurologists and clinical engineers confirmed the data via the Internet through personal computers at appropriate times using a remote monitoring system (CareLink, Medtronic Inc.). When PAF was detected, patients were requested to visit our hospital by telephone, and data on long-hour waveforms were collected using a CareLink 2090 Programmer (Medtronic Inc.) or CareLink Express (Medtronic Inc.). As a rule, we requested physicians specializing in arrhythmia to confirm the diagnosis of PAF. When a diagnosis of PAF was made, the secondary prophylactic drug was switched to a direct oral anticoagulant (DOAC) as a rule. When symptoms, such as palpitation, were present on PAF, patients were referred to physicians specializing in arrhythmia to assess the indications of drug therapy or catheter ablation. A procedure using a Penumbra aspiration catheter (Penumbra Inc., Alameda, CA, USA) and stent-type devices for thrombectomy (Solitaire FR: Medtronic; Trevo XP: Stryker Neurovascular, Fremont, CA, USA; Revive: Codman, Johnson & Johnson, Miami, FL, USA) was defined as thrombectomy. Clinical parameters were expressed as the median (interquartile range [IQR]) (number [%]). Regarding the date of device insertion as day 0, survival analyses were conducted. All data were analyzed using JMP version 12.0.1 software (SAS Institute, Cary, NC, USA).
Results
The patient background is shown in Table 1 . The median age was 68 years (range: 59-76 years). There were eight males (80%). Regarding PAF-associated parameters, the median brain natriuretic peptide (BNP) level, D-dimer level, premature atrial contractions on Holter ECG, and left atrial appendage blood flow velocity at the time of outflow/inflow on TEE were 29 (8.8-56) pg/mL, 0.69 (0.62-0.78) pg/mL, 6 (2-129) beats/day, and 69 (57-96)/63 (48-64) cm/s, respectively. There were no significant abnormal findings other than a slight increase in the BNP level ( Table 1) . The median Congestive heart failure/LV dysfunction, Hypertension, Age ≥75y, Diabetes m ellitus, Stroke/TIA (CHADS 2 ) score was 3 (2.75-3.25) and the median National Institutes of Health Stroke Scale (NIHSS) score was 15 (9-21). Of 10 patients in whom an ICM device was inserted, the median interval from the onset of cerebral infarction until ICM device insertion was 17 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) days. In all patients, the device was inserted during admission due to acute-phase cerebral infarction. The internal carotid artery was occluded in two patients (20%), the proximal middle cerebral artery in Cryptogenic stroke n=20 (20%) two (20%), the distal middle cerebral artery in two (20%), the M2 middle cerebral artery in three (30%), and the basilar artery in one patient (10%); occlusion of the internal carotid or middle cerebral arteries was frequently observed. The frequency of passing a stent-type device for thrombectomy was once in eight patients (80%). Effective recanalization (thrombolysis in cerebral infarction [TICI] classification: 2b and 3) was achieved in 10 patients (100%). In six patients (60%), PAF was detected within 1 year after insertion. Of these patients, the interval until PAF detection was ≤1 month in 3, 187 days in 1, 318 days in 1, and 421 days in 1. The median interval from implantation until PAF detection was 52 (12-344) days (Fig. 2) . For all six patients in whom PAF was detected, Warfarin had been used as a secondary prophylactic drug for cerebral infarction, but it was switched to a DOAC. Catheter ablation was performed for three (50%) of the six patients. In one, the maximum R-wave value after insertion was <0.2 mV, requiring additional insertion. However, there were no other complications on or after insertion. Monitoring was conducted by neurologists using a remote monitoring system (CareLink). When PAF was detected, the secondary prophylactic drug was changed to a DOAC at the outpatient clinic by contacting the patients or their families.
Discussion
In this study, the detection rate of PAF on ICM in CS patients after thrombectomy was 60%. Furthermore, the TICI 2b-3 recanalization rate was 100%. The number of passing a stent-type device for thrombectomy was one in 80%, suggesting that thrombectomy was relatively simple. As an etiological factor for CS, latent AF has been emphasized. On March 22, 2016, the use of an ICM device in patients with CS was pharmaceutically approved. The detection rate of latent AF increases with prolongation of the measurement time. According to a previous study, AF was newly detected in 7.7%, 5.1%, 10.7%, and 16.9%, respectively, through sequential sessions of measurement in 4 phases: "ECG on the initial consultation," "electrocardiographic monitoring/Holter ECG during admission," "monitoring with a portable Holter ECG at the outpatient clinic," and "outpatient telemetry/extracorporeal settingtype recorder/ICM"; latent AF was identified in 23.7% of the patients through four phases, 6) suggesting the importance of long-term monitoring. In this study, the maximum observation period was 421 days (approximately 1 year), being shorter than that in previous studies using ICM. The CRYSTAL AF study reported a detection rate of PAF on ICM within 3 months in CS patients of 12%. 2) The REVEAL AF study reported detection rates within 30 days and 6 months of 6.2% and 20.4%, respectively. 7) According to Poli et al., the detection rate within 6 months was 28%, 8) 13) respectively, with a mean interval of 281 and 569 days from the onset of CS until PAF detection, respectively. In Japan, the "Guidelines for the diagnosis of cryptogenic stroke patients for whom an insertable cardiac monitoring device may be indicated" were prepared by the Japan Stroke Society. In the guidelines, diagnostic procedures for CS patients are described in detail. 4) In this study, PAF was detected within 1 year in 40% of CS patients in whom an ICM device was inserted at our hospital in accordance with the guidelines. 14 3) demonstrated that 33% of all patients had a history of AF; therefore, PAF may be present in stroke patients with acute LVO. Furthermore, in this study, the median interval from the onset of cerebral infarction until ICM device implantation was 17 (10-22) days; implantation was conducted relatively early. Carrazco et al. reported that the median interval until the detection of PAF was 34 (0-514) days, with a mean interval of 4.2 ± 2.6 days from admission until ICM device implantation, and that the detection rate of PAF within 18 months was 31%. 20) These results suggest that the detection rate of PAF increases if the interval from the onset of cerebral infarction until ICM device implantation is short. In this study, implantation was performed in the early phase, as previously reported, and the detection rate of PAF was high. However, this may have been related to thrombectomy regardless of the timing of implantation.
This study has four limitations. First, the number of patients was limited. Second, this was a retrospective study involving a small number of patients. Third, the follow-up period was short. Fourth, the use of ICM devices increased the cost. In the future, long-term follow-up should be conducted for a larger number of patients.
Conclusion
The detection rate of PAF on ICM in CS patients who were treated by endovascular therapy at our hospital was approximately 60% within a year, being higher than that previously reported. An ICM device should be positively used to detect PAF in CS patients after thrombectomy.
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